The United States Food and Drug Administration approved Zanvastro, or zilganersen, on 3 September 2026 for paediatric and adult patients with Alexander disease. It is the first FDA-approved therapy for the disorder and the first designed to target the protein accumulation that drives it.
For an ultra-rare neurological disease that previously had only supportive care, that is a major regulatory milestone. It is also a case where careful reading matters: patient numbers are necessarily small, age groups were assessed differently and long-term evidence will continue to develop after approval.
What Alexander disease is
Alexander disease is caused by mutations affecting the gene for glial fibrillary acidic protein, usually abbreviated GFAP. Abnormal GFAP accumulates in supportive cells in the brain, damaging the nervous system over time.
The condition affects fewer than one person in a million. Its course and symptoms vary, but they can include seizures, loss of developmental milestones, difficulty walking, muscle weakness and increased pressure in the brain.
Zanvastro is an antisense oligonucleotide. It is designed to reduce production of the abnormal GFAP protein before it builds up. The medicine is injected into the spinal canal every three months by a trained healthcare professional.
What the study found
The FDA assessed a multicentre randomised controlled study identified as NCT04849741. It enrolled 49 paediatric and adult patients aged two years or older, alongside an open-label substudy of four patients younger than two.
For participants aged five and older who had measurable walking difficulty at baseline, the treated group showed significantly better walking speed at 61 weeks than the untreated group. For children aged two to four, researchers used a broader measure of gross motor abilities because walking speed alone is not an appropriate outcome for that age. Treated children improved on that measure while the control group declined.
Evidence for children under two was more limited. The FDA used pharmacokinetic modelling, together with safety observations from four treated infants, to support the indication across the youngest age group.
Safety and uncertainty
The most common reported side effects include vomiting, back pain, cough, headache and post-lumbar-puncture syndrome. Aseptic meningitis has also been reported, and the FDA advises patients and caregivers to discuss relevant symptoms with their healthcare provider.
Approval does not mean every uncertainty is resolved. The disease is exceptionally rare, the trial population is small and evidence for infants is especially limited. Longer follow-up and real-world data will be needed to understand durability, rare adverse effects and differences across the broad spectrum of the disease.
Why this milestone matters
Rare-disease development is constrained by small populations and heterogeneous symptoms. Regulators must decide how to combine controlled evidence, age-appropriate outcomes and modelling without pretending that limited data are complete data.
Zanvastro illustrates both sides of that challenge. The therapy targets a known disease mechanism and produced measurable clinical evidence. The approval also rests on different kinds of support across age groups, which should remain visible in public reporting.
The Mythic Mode perspective
Scientific progress is clearest when hope and uncertainty can coexist. Families now have the first approved treatment aimed at the underlying process of Alexander disease. Clinicians and researchers still need to learn how benefits and risks develop over years and across individual patients.
This article is general information and does not replace medical advice. Treatment decisions belong with qualified clinicians who can assess the full prescribing information and an individual's circumstances.